Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. September 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem and NIAID Met With U.S. FDA and Agreed on Development Plan for Initiation of Pivotal Study of PLX-R18 in the Treatment of Acute Radiation Syndrome

HAIFA, Israel, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that Pluristem...
10. September 2015 04:31 ET | Quelle: Pluri Inc.

Pluristem Provides Corporate and Financial Highlights for Fiscal Year 2015

HAIFA, Israel, Sept. 10, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, reported yesterday financial...
09. September 2015 04:00 ET | Quelle: Pluri Inc.

Pluristem Completed Successful Meeting With the U.S. FDA in Preparation for Filing an IND for PLX-R18 to Treat Incomplete Hematopoietic Recovery After Bone Marrow Transplantation

HAIFA, Israel, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has...
06. September 2015 07:00 ET | Quelle: Pluri Inc.

Pluristem President Yaky Yanay Elected as Co-Chairman of Israel Advanced Technology Industries

HAIFA, Israel, Sept. 6, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced its President and...
17. August 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications

HAIFA, Israel, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that the U.S....
12. August 2015 04:00 ET | Quelle: Pluri Inc.

Japan Grants Safety Clearance to Pluristem's PLX-PAD Cells for Use in Clinical Trials

HAIFA, Israel, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that Japan's...
10. August 2015 03:00 ET | Quelle: Pluri Inc.

Pluristem in Key Discussions With Europe's Adaptive Pathways Group on Phase II Protocol in Critical Limb Ischemia

HAIFA, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has...
27. Juli 2015 03:00 ET | Quelle: Pluri Inc.

New Data Show Pluristem's PLX Cells Regulate the Immune System

HAIFA, Israel, July 27, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced the publication of...
25. Juni 2015 09:21 ET | Quelle: Pluri Inc.

Pluristem Therapeutics Announces Pricing of Registered Direct Offering of Common Stock and Warrants

HAIFA, Israel, June 25, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) today announced that it has entered into definitive agreements to sell 6,800,000 shares of common...
24. Juni 2015 03:15 ET | Quelle: Pluri Inc.

Pluristem Granted Australian Patent for 3D Cell Expansion Technology & Use of PLX Cells in Broad Range of Indications

HAIFA, Israel, June 24, 2015 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that it has been...

Vorherige Seite

Nächste Seite